skip to content


Issue No. 6 | February 4, 2011

News and Features

Join AIDSinfo in Observing National Black HIV/AIDS Awareness Day

February 7, 2011, marks the 11th annual National Black HIV/AIDS Awareness Day. According to the 2008 HIV Surveillance Report  from the Centers for Disease Control and Prevention (CDC), African Americans accounted for 52% of all HIV infection diagnoses in the United States in 2008. National Black HIV/AIDS Awareness Day is a community-based initiative that encourages HIV/AIDS education, testing, and treatment to combat the HIV/AIDS epidemic in the African-American community.

AIDSinfo has developed a specialty page for this awareness day with information and resources about HIV/AIDS and African Americans.

More information is available:

CDC Issues MMWR on Interim Guidance for PrEP in MSM

“An estimated 56,000 human immunodeficiency virus (HIV) infections occur each year in the United States … . Men who have sex with men (MSM) account for 53% of the estimated incident infections, and surveillance data suggest that the annual number of new HIV infections among MSM has been rising since the mid-1990s … . … On November 23, 2010, investigators for the Pre-Exposure Prophylaxis Initiative (iPrEX) study announced results from a multinational, randomized, double-blind, placebo-controlled, phase III clinical trial of daily oral antiretrovirals (tenofovir disoproxil fumarate [TDF] and emtricitabine [FTC]) to prevent acquisition of HIV infection among uninfected but exposed MSM … . This report provides interim guidance to health-care providers based on the reported results of that trial, which indicated that TDF plus FTC taken orally once a day as preexposure prophylaxis (PrEP) is safe and partially effective in reducing HIV acquisition among MSM when provided with regular monitoring of HIV status and ongoing risk-reduction and PrEP medication adherence counseling. …

“Based on the results of this study, CDC and other U.S. Public Health Service (PHS) agencies have begun to develop PHS guidelines on the use of PrEP for MSM at high risk for HIV acquisition in the United States as part of a comprehensive set of HIV prevention services. Completing the guidelines and obtaining expert input and public comment will take several months before they can be published. … Until the more detailed PHS guidelines are available, CDC is providing interim recommendations to help guide clinical practice … .”

More information is available:

Study Suggests Viral Suppression in Salvage Treatment With Raltegravir Improved With Partially Active or Inactive Nucleoside Reverse Transcriptase Inhibitors

“Nucleoside reverse transcriptase inhibitors (NRTIs) are often administered in salvage therapy even if genotypic resistance tests (GRTs) indicate high-level resistance, but little is known about the benefit of these additional NRTIs. ...

“The effect of <2 compared to 2 NRTIs on viral suppression (HIV-1 RNA <50 copies/mL) at week 24 was studied in salvage patients receiving raltegravir (RAL). …

“130 patients were included, of whom 58.5% (n=76) received <2 NRTIs. NRTIs were often replaced by other drug classes. Patients with 2 NRTIs received less additional drug classes compared to patients with <2 NRTIs … . The activity of non-NRTI treatment components was lower in the 2 NRTIs group compared to the <2 NRTIs group … . The administration of <2 NRTIs was associated with a worse viral suppression rate at week 24. …

“Our findings showed that partially active or inactive NRTIs contribute to treatment response, and thus the use of 2 NRTIs in salvage regimens that include raltegravir seems warranted.”

More information is available: